New bronchodilators

Current Opinion in Pharmacology

Volumn 12, Issue 3, 2012, Pages 238-245

  Mak, Garbo ^a   Hanania, Nicola A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABEDITEROL; ACEBROPHYLLINE; ACLIDINIUM BROMIDE; AZD 3199; BAMIFYLLINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BI 1744CL; BRONCHODILATING AGENT; CHF 5407; CICLESONIDE; CORTICOSTEROID; DOXOFYLLINE; FLUTICASONE PROPIONATE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PF 4522971; PF 610355; PHOSPHODIESTERASE INHIBITOR; PLACEBO; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TROSPIUM CHLORIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL; XANTHINE DERIVATIVE;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HUMAN; LIPOPHILICITY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 84862275011     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.02.019     Document Type: Review

References (53)

1. Morbidity & Mortality Chart Book on Cardiovascular, Lung and Blood Diseases 2009 National Heart, Lung and Blood Institute
2. H.B. Bosworth, B.B. Granger, P. Mendys, R. Brindis, R. Burkholder, S.M. Czajkowski, J.G. Daniel, I. Ekman, M. Ho, and M. Johnson Medication adherence: a call for action Am Heart J 162 2011 412 424
3. D. Lombardi, B. Cuenoud, and S.D. Kramer Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 38 2009 533 547
4. 2-adrenoceptor agonist J Med Chem 53 2010 3675 3684
5. E.M. Rosethorne, R.J. Turner, R.A. Fairhurst, and S.J. Charlton Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists Naunyn Schmiedebergs Arch Pharmacol 382 2010 255 263
6. P. Casarosa, I. Kollak, T. Kiechle, A. Ostermann, A. Schnapp, R. Kiesling, M. Pieper, P. Sieger, and F. Gantner Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol J Pharmacol Exp Ther 337 2011 600 609
7. B.A. Chowdhury, S.M. Seymour, T.M. Michele, A.G. Durmowicz, D. Liu, and C.J. Rosebraugh The risks and benefits of indacaterol - the FDA's review N Engl J Med 365 2011 2247 2249
8. D. Renard, M. Looby, B. Kramer, D. Lawrence, D. Morris, and D.R. Stanski Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches Respir Res 12 2011 54
9. M. Cazzola, A. Proietto, and Matera MG: Indacaterol for chronic obstructive pulmonary disease (COPD) Drugs Today (Barc) 46 2010 139 150
10. 2-agonist, on isolated human bronchi Eur Respir J 29 2007 575 581
11. C. Battram, S.J. Charlton, B. Cuenoud, M.R. Dowling, R.A. Fairhurst, D. Farr, J.R. Fozard, J.R. Leighton-Davies, C.A. Lewis, and L. McEvoy In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2- ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quino lin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action J Pharmacol Exp Ther 317 2006 762 770
12. B. Balint, H. Watz, C. Amos, R. Owen, M. Higgins, and B. Kramer Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone Int J Chron Obstruct Pulmon Dis 5 2010 311 318
13. M.D. Moen Indacaterol: in chronic obstructive pulmonary disease Drugs 70 2010 2269 2280
14. 2-adrenoceptor agonist with a 24 h bronchodilatory efficacy Bioorg Med Chem Lett 20 2010 1410 1414
15. 2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models J Pharmacol Exp Ther 334 2010 53 62
16. J.A. van Noord, J.J. Smeets, B.M. Drenth, J. Rascher, A. Pivovarova, A.L. Hamilton, and P.J. Cornelissen 24-Hour bronchodilation following a single dose of the novel beta(2)-agonist olodaterol in COPD Pulm Pharmacol Ther 24 2011 666 672
17. 2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach J Med Chem 53 2010 4522 4530
18. A.J. Ford, S. Hughes, V. Morrison, V.J. Barrett, and R. Knowles In vitro and in vivo pharmacological characterisation of GW642444, a novel long-acting B2 agonist (LABA), with fast onset and long duration in the guinea-pig Am J Respir Crit Care Med 181 2010 A5677 [abstract]
19. N.A. Hanania, G. Feldman, W. Zachgo, J.J. Shim, C. Crim, L. Sanford, S. Lettis, F. Barnhart, and B. Haumann The efficacy and safety of the novel long-acting B2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial Chest 2012 10.1378/chest.11-2231 Epub ahead of print
20. M. Aparici, M. Gomez-Angelats, D. Vilella, J. Cortijo, E.J. Morcillo, C. Carcasona, A. Gavalda, J. Beleta, C. Puig, H. Ryder, and M. Miralpeix The in vitro pharmacological profile of LAS100977 - a potent, selective and long-acting beta-2 receptor agonist Am J Respir Crit Care Med 181 2010 A5675 [abstract]
21. W. Timmer, E. Massana, E. Jimenez, B. Seoane, G. de Miquel, and S. Ruiz Single doses of LAS100977, a novel long acting B2-agonist, show high activity and long duration in healthy subjects Am J Respir Crit Care Med 181 2010 A5663 [abstract]
22. P.A. Glossop, C.A. Lane, D.A. Price, M.E. Bunnage, R.A. Lewthwaite, K. James, A.D. Brown, M. Yeadon, C. Perros-Huguet, and M.A. Trevethick Inhalation by design: novel ultra-long-acting B(2)-adrenoceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup J Med Chem 53 2010 6640 6652
23. G.L. Li, F. MacInyre, B. Surujbally, C.L. Chong, and J. Davis Pharmacokinetics of PF-00610355, a novel inhaled long-acting B2-adrenoreceptor agonist Eur Respir J 34 2009 777s [abstract]
24. A. Young, D.C.S. Nicholis, R.V. Bonnert, E.B. Pairaudeau, E.B. Cadogan, M.J. Stocks, S.M. Jordan, S. Paine, and P. Gardiner The in vivo profile of AZD3199: a novel, fast acting B2-agonist with a long duration of action Am J Respir Crit Care Med 183 2011 A1586 [abstract]
25. P. Kuna, Y. Ivanov, V. Trofimov, O. Beckman, T. Bengtsson, C. Jorup, and F. Maltais Efficacy and safety of AZD3199, an inhaled ultra long-acting B2-agonist, in patients with COPD Eur Respir J 38 2011 148s [abstract]
26. K. Wu, M. Looby, G. Pillai, G. Pinault, A.F. Drollman, and S. Pascoe Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients J Pharmacokinet Pharmacodyn 38 2011 105 119
27. M.G. Matera, C.P. Page, and M. Cazzola Novel bronchodilators for the treatment of chronic obstructive pulmonary disease Trends Pharmacol Sci 32 2011 495 506
28. A. Gavalda, M. Miralpeix, I. Ramos, R. Otal, C. Carreno, M. Vinals, T. Domenech, C. Carcasona, B. Reyes, and D. Vilella Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile J Pharmacol Exp Ther 331 2009 740 751
29. M.W. Sims, and R.A. Panettieri Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 6 2011 457 466
30. P.W. Jones, S.I. Rennard, A. Agusti, P. Chanez, H. Magnussen, L. Fabbri, J.F. Donohue, E.D. Bateman, N.J. Gross, and R. Lamarca Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease Respir Res 12 2011 55
31. A. Gelb, J. Donohue, A. D'Urzo, L. Rekeda, E. Garcia Gil, and J. Lateiner ACCORD COPD I: twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients Eur Respir J 38 2011 149s 150s [abstract]
32. C. Verkindre, Y. Fukuchi, A. Flemale, A. Takeda, T. Overend, N. Prasad, and M. Dolker Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients Respir Med 104 2010 1482 1489
33. P. Casarosa, T. Bouyssou, S. Germeyer, A. Schnapp, F. Gantner, and M. Pieper Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs J Pharmacol Exp Ther 330 2009 660 668
34. C. Fogarty, H. Hattersley, S.L. Di, and A. Drollmann Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Respir Med 105 2011 337 342
35. A. D'Urzo, F. Ferguson, M. Kato, S. Atis, C. Martin, V.K.T. Alagappan, D. Banerji, Y. Lu, and T. Overend NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: the GLOW1 trial Eur Respir J 38 2011 147s [abstract]
36. J.A. van Noord, K. Hirata, C. Martin, R. Horton, Y. Lu, and T. Overend NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: the GLOW1 trial Eur Respir J 38 2011 147s [abstract]
37. D.I. Laine, M.A. Luttman, J.J. Foley, C.J. Dehaas, C.J. Kotzer, M. Salmon, and W.L. Rumsey The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing Eur Respir J 38 2011 613s [abstract]
38. M. Decramer, F. Maltais, G. Feldman, J. Brooks, L. Willits, S. Harris, and G. Crater Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Eur Respir J 38 2011 150s [abstract]
39. G. Villetti, F. Pastore, M. Bergamaschi, F. Bassani, P.T. Bolzoni, L. Battipaglia, G. Amari, A. Rizzi, M. Delcanale, and R. Volta Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist J Pharmacol Exp Ther 335 2010 622 635
40. S. Patel, S. Marshall, S. Summerhill, M. Strawbridge, M. Stanley, E. Stuart, M. Trevethick, M. Yeadon, and N. Clarke The in vitro pharmacology of PF-4522971 - a novel inhaled muscarinic M3 antagonist Eur Respir J 36 2010 219s [abstract]
41. L. Oleson, R.Z. Turncliff, B. Silverman, C. Fogarty, and E. Ehrich ALKS 27 (Trospium Inhalation Powder) improves lung function following single administration in subjects with COPD Am J Respir Crit Care Med 2010 181 [abstract]
42. C.P. Page Doxofylline: a "novofylline" Pulm Pharmacol Ther 23 2010 231 234
43. 2-agonists and muscarinic antagonists in COPD Pulm Pharmacol Ther 23 2010 257 267
44. K.F. Chung, G. Caramori, and I.M. Adcock Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future Eur J Clin Pharmacol 65 2009 853 871
45. A.D. Hughes, K.H. Chin, S.L. Dunham, J.R. Jasper, K.E. King, T.W. Lee, M. Mammen, J. Martin, and T. Steinfeld Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules Bioorg Med Chem Lett 21 2011 1354 1358
46. J. Buckley, M.A. Birrell, S.A. Maher, A.T. Nials, D.L. Clarke, and Belvisi MG: EP4 receptor as a new target for bronchodilator therapy Thorax 66 2011 1029 1035
47. D.A. Deshpande, W.C. Wang, E.L. McIlmoyle, K.S. Robinett, R.M. Schillinger, S.S. An, J.S. Sham, and S.B. Liggett Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction Nat Med 16 2010 1299 1304
48. K.H. Banner, and N.J. Press Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease Br J Pharmacol 157 2009 892 906
49. G. Feldman, T. Siler, N. Prasad, D. Jack, S. Piggott, R. Owen, M. Higgins, and B. Kramer Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study BMC Pulm Med 10 2010 11
50. J.F. Donohue, C. Fogarty, J. Lotvall, D.A. Mahler, H. Worth, A. Yorgancioglu, A. Iqbal, J. Swales, R. Owen, M. Higgins, and B. Kramer Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
51. 2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
52. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, C. Lassen, and B. Kramer Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2011 273 279
53. S. Korn, E. Kerwin, S. Atis, C. Amos, R. Owen, and C. Lassen Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study Respir Med 105 2011 719 726